Grail (NASDAQ:GRAL) Now Covered by Analysts at Guggenheim

Guggenheim began coverage on shares of Grail (NASDAQ:GRAL) in a research report report published on Thursday morning, Marketbeat reports. The brokerage issued a neutral rating on the stock.

Grail Stock Up 3.9 %

Shares of NASDAQ:GRAL opened at $14.76 on Thursday. The firm’s fifty day moving average is $14.19. Grail has a 1-year low of $12.33 and a 1-year high of $23.36.

Grail (NASDAQ:GRAL) last issued its earnings results on Tuesday, August 13th. The company reported ($5.30) earnings per share (EPS) for the quarter. The business had revenue of $31.97 million for the quarter.

Insiders Place Their Bets

In other news, CEO Robert P. Ragusa sold 123,454 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the transaction, the chief executive officer now directly owns 612,661 shares of the company’s stock, valued at $8,589,507.22. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, major shareholder Chun R. Ding purchased 16,200 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were purchased at an average price of $12.92 per share, with a total value of $209,304.00. Following the acquisition, the insider now directly owns 3,644,855 shares in the company, valued at $47,091,526.60. The trade was a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Ragusa sold 123,454 shares of Grail stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the completion of the sale, the chief executive officer now owns 612,661 shares of the company’s stock, valued at $8,589,507.22. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders acquired 58,829 shares of company stock valued at $757,298.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.